Shots:
- BehaVR to receive $5M up front, ~$18M in development milestone and R&D support along with commercial & operational support fees and is eligible to receive $140M in milestone upon commercial success along with royalties on global sales of the digital therapeutic products
- The collaboration combines BehaVR’s development capabilities with SDP’s expertise to develop prescription therapeutics for the treatment of CNS-related disorders
- SDP has accepted to fund the development of novel VR therapies & to commercialize globally. In Jun’20, the companies signed an initial collaboration agreement to co-develop a wellness product for patients with overwhelming feelings in a social setting
Click here to read full press release/ article | Ref: PRNewswire | Image: PRNewswire
The post Sumitomo Dainippon Pharma Signs a Definitive Agreement with BehaVR to Develop and Commercialize PDTs and Wellness Product for CNS Disorders first appeared on PharmaShots.
